Tonix Pharmaceuticals (TNXP +4.7%) inks an agreement with
the University of Alberta for exclusive rights to three COVID-19
vaccine candidates, dubbed TNX-1810, TNX-1820 and TNX-1830, all based on
a horsepox vector platform and designed to elicit almost 100% T cell
responses.
The parties will collaborate on development.
Financial terms remain confidential.
https://seekingalpha.com/news/3571302-tonix-pharma-secures-rights-to-three-covidminus-19-vaccine-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.